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ABSTRACT  
Myocardial infraction (AMI) is an irreversible myocardial injury and necrosis caused by serious and long-term ischemia. It is generally seen in 
middle aged men with high risk factors for coronary artery disease. Only 4% of patients with AMI are under 40 years of age. This was a cross 
sectional study conducted at AL SHAB hospital, Khartoum, Sudan, aimed to estimate the fibrinogen level among Sudanese patients with 
myocardial infraction. 50 patients attending Alshab Hospital and diagnosed with MI used as a case group and 50 apparently healthy individuals 
with no history of MI were selected as control group. 1.8 ml of blood samples has been collected in sodium citrate anticoagulant container for 
measurement of fibrinogen level by clauss method in coagulometer device. It is clearly significant increase in fibrinogen level in myocardial 
infraction patient (p.value 0.000). In addition, the prothrombin time and gender were insignificantly differences in (AMI) patients. In the other 
hand, age and smoking significantly increased as risk factor in myocardial infraction. This study concluded that fibrinogen level was 
significantly increased in Sudanese patients with  myocardial infraction. 
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INTRODUCTION 
Acute myocardial infarction (AMI) is an irreversible 
myocardial injury and necrosis caused by serious and long-
term ischemia. It is generally seen in middle aged men with 
high risk factors for coronary artery disease. Only 4% of 
patients with AMI are under 40 years of age. Coronary 
anatomy is normal in 30% of young AMI patients. The 
presence of normal coronary anatomy is related to coronary 
vasospasm, embolism from endocardium or heart vessels 
and platelet aggregation or spontaneous lysis of thrombus.[1] 
The morbidity and mortality rates of ACS are increasing, 
thus, Premature myocardial infarction with life threatening 
complications may become epidemic in some Asian and 
African countries Deaths per 1000 person-years in the 
quartile (P,0.001 for trend). [2].  
Pathogenicity  
Instability of coronary atherosclerosis plaque, which is easily 
to rupture that, may induce platelet aggregation and lead to 
complete or incomplete coronary artery embolism. Further 
causes severe lumen stenosis and myocardial blood supply 
shortage. At present, the treatment principle of ACS is early 
detection, early diagnosis and early treatment to achieve 
revascularization. In recent years, with the development in 
Chest Pain Center and interventional technology, ACS 
patients can receive timely treatment. However, research has 
found that some ACS patients would still develop major 
adverse cardiovascular events (MACEs) even after getting 
through the acute phase; MACEs can cause serious threats to 
the quality of life and even lead to death of patients. 
Therefore, predicting the short term prognosis for ACS 
patients is one of the hot issues that draw clinical attention. 
The pathological basis of ACS is thrombosis caused by 
abnormal fibrinolysis and blood coagulation and the 
pathological basis of MACE is the formation of sub-acute or 
chronic coronary embolism. In recent years, the researches 
confirmed that there was a correlation between the 
prognosis of patients with ACS and diverse biochemical 
markers. Its immunocompetence fragment can reflect the 
plasma concentration of cross linked fibrin polymer and its 
plasma level can effectively and specifically reflect the 
increase in blood circulating coagulation and the level of 
secondary fibrinolytic hyperactivity [3].  
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AMI is diagnosed where there are at least two of following; 
chest pain longer than 30 minutes which does not respond to 
nitrates, in 12-lead electrocardiography, a new Q wave 
longer than 40 ms and/or ST segment elevation 0.1 mV on at 
least two extremity derivations or 0.2 mV on precordial 
derivation, a 1.5 times, or higher, increase in serum creatin-
phosphokinase-MB and TT, Fibrinogen well elevated.[3]  
Fibrinogen level  
Fibrinogen is one of 13 coagulation factors responsible for 
normal blood clotting and made in the liver, also known as 
factor 1 [4] . When bleeding start the body initiates process 
called coagulation cascade or clotting cascade, this process 
cause coagulation factor to combine and produce a clot that 
will stop the bleeding. If the body hasn’t enough fibrinogen 
or if the cascade isn’t working normally clots will have 
difficulty forming, this can cause excessive bleeding. [5]  
Low fibrinogen levels can also cause thrombosis in 
coagulation activity. Thrombosis refers to the formation of 
blood clot inside of blood vessel. The clot blocks normal 
blood flow through the circulatory system. This can lead to 
serious medical condition such as heart attack and stroke [6]. 
Numerous prospective epidemiological studies have 
reported positive associations between the risk of coronary 
heart disease (CHD) and plasma fibrinogen levels. [7]. 
Fibrinogen levels decreased considerably by lifestyle 
interventions that also affect levels of risk factors such as 
regular exercise, smoking discontinuation  and moderate 
alcohol consumption, the measurement of fibrinogen level 
may help in disease prediction or prevention. [8] This study 
aimed to estimate the fibrinogen level among Sudanese 
patients with myocardial infraction. 
MATERIALS AND METHODS  
This is a cross sectional study, conducted at  Alshab Hospital, 
Khartoum, Sudan during  the period May 2019 to July 2019.  
All patients attending Alshab Hospital and diagnosed with MI 
during the aforementioned period were included. In addition 
to that, apparently healthy individuals with no history of MI 
were selected as control group. The study was approved by 
the ethical committee of  Al shab Hospital,  The data was 
collected using pre-designed structural questionnaire, the 
demographic and clinical data concerning each participant 
was obtained from the registry data base office, which 
included the following information: (Gender, age, weight, 
smoking, chronic disease, treatment, exercise and medical 
history). The laboratory data included hematological results 
and fibrinogen level findings. 2.8 ml of blood samples were   
collected in trisodium citrate anticoagulant container for 
fibrinogen level count.  
Tests procedure 
1. Thrombin time  
75 µl of thrombin solution added to 100 µl of tested plasma 
in cuvette at 37ºc and start reading of clotting time. 
Sample diluted in 1:10 in imidazole buffer 
Normal range: up to 10__12 second. 
2. prothrombin time   
100µl of thrombin solution was added to 100 µl of tested 
plasma in cuvette at 37ºc and reading of clotting time was 
recorded. 
Normal range: up to 11__ 13.5second. 
3 .Fibrinogen assay 
The preparation of   calibration/standard plasma dilution in 
Imidazole buffer was followed; 1:5(200%)-1:10(100%)-
1:20(50%)-1:30(33%)-1:40(25%). Firstly 0.1ml of each 
dilution was incubated at 37C for 120 seconds, then 0.075ml 
of thrombin solution was added and simultaneously start 
reading, the clot was observed and clot time was measured 
nearest to 0.1seconds. The polt calibration curve on log- log 
graph paper and the clot time versus the fibrinogen 
concentration in g/l the curve was obtained by the linear. 
The dilute control plasma or patient sample 1:10 in 
Imidazole buffer. The normal reference for fibrinogen is 
generally 1.5-3.5g/l (150—350mg/dl) 
RESULTS 
In the present study 50 of myocardial infraction patients 
were included. Among them, 35 were males, while 15 were 
females. In addition, 50 of apparently healthy individuals 
were selected as control group, 19 were males, while 31 
were female.  (fig 1). The most affected age group in the 
patients was more than 60 years followed by 51-60 years 
which constituted 52% and 26%, respectively (Table 1). 
The hematological parameters revealed that, when 
compared the age group with thrombin time and fibrinogen 
level among the patient gave significant result (P = 0.000) 
(table 5) . Also, there was insignificant result when 
Comparison of age (p = 0.866), Weight (p = 0.520), PT (p = 
0.617), INR (p = 0.422) (table 6), but significant in TT (p = 
0.002) and Fibrinogen level (p=0.008) among gender of MI 
patients (table 6). When Comparison of PT (p=0.229), INR 
(p=0.422), TT (p = 0.159) and Fibrinogen level (p = 0.146) 
among patients used treatment of chronic disease (diabetes 
and hypertension) there was insignificant result (table7). 
Also when Comparison of PT (p=0.068), INR (p = 0.134) 
among smoker gave insignificant result, while the TT (p = 
0.000), and Fibrinogen level (p=0.000) among smoker 
patients gave significant result (table 8). While, there was 
significant difference when correlation between weight and 
TT (second). In addition to that, there was significant 
difference between weight and fibrinogen levels (mg/dl).  
Table (1): Age groups of affected patients 
Age groups frequency Percent 
Less than 30 2 4.0 
31-40 1 2.0 
41-50 8 16.0 
51-60 13 26.0 
More than 60 26 25.0 
Total 50 100.0 
 
Table (2):  Frequency of smoking among affected 
patients 
Smoking Frequency Percent 
NO 33 66.0 
Yes 17 34.0 
Total 50 100.0 
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Table (3): Descriptive statistics for myocardial infarction patients 
Variable  N Minimum Maximum Mean Std. Deviation 
Age (years) 50 20 90 61.5 14.2 
Weight (kg) 50 47 90 74.9 7.9 
PT (seconds) 50 13.7 19.8 16.4 1.3 
INR 50 0.9 1.4 1.1 0.13 
TT (seconds) 50 17.5 25.0 20.9 2.2 
Fibrinogen (mg/dl) 50 421 602 505.1 53.2 
 
Table (4): Descriptive statistics for control 
 N Minimum Maximum Mean Std. Deviation 
Age (years) 50 22 36 28.9 3.9 
TT (seconds) 50 9.9 12.0 10.7 0.7 
Fibrinogen (mg/dl) 50 238 290 260.3 15.8 
 
 
 
Fig (1): Frequency of gender among study population 
Table (5): Comparison of age, TT and Fibrinogen level among population study 
Parameters Population study  
(Mean ± SD)  
P. value 
MI patients  (n=50) Control   (n=50) 
Age (years) 61.5 ± 14.2 28.9 ± 3.9 0.000 
TT (seconds) 20.9 ± 2.2 10.7 ± 0.7 0.000 
Fibrinogen (mg/dl) 505.1 ± 53.2 260.3 ± 15.8 0.000 
 
Table (6): Comparison of age, Weight, PT, INR, TT and Fibrinogen level among gender of MI patients 
Parameters Gender  
(Mean ± SD)  
P. value 
Male  (n=35) Female  (n=15) 
Age (years) 61.3 ± 14.5 62.1 ± 13.9 0.866 
Weight (kg) 74.3 ± 6.3 76.3 ± 11.1 0.520 
PT (seconds) 16.5 ± 1.3 16.2 ± 1.6 0.617 
INR 1.1± 0.13 1.1± 0.15 0.422 
TT (seconds) 21.5 ± 2.2 19.7 ± 1.6 0.002 
Fibrinogen (mg/dl) 517.8 ± 52.8 475.4 ± 42.6 0.008 
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Table (7): Comparison of PT, INR, TT and Fibrinogen level among patients use treatment of chronic disease 
Parameters Treatment  
(Mean ± SD)  
P. value 
No  (n=35) Yes  (n=15) 
PT (seconds) 16.2 ± 1.4 16.7 ± 1.2 0.229 
INR 1.1± 0.1 1.1± 0.1 0.422 
TT (seconds) 21.3 ± 2.2 20.3 ± 1.9 0.159 
Fibrinogen (mg/dl) 512.3 ± 54.4 488.3 ± 48.1 0.146 
 
 
 
Fig (2): Frequency of use treatment for chronic diseases among gender 
 
Table (8): Comparison of PT, INR, TT and Fibrinogen level among smoker 
Parameters Smoking  
(Mean ± SD)  
P. value 
No  (n=33) Yes  (n=17) 
PT (seconds) 16.1 ± 1.3 16.9 ± 1.3 0.068 
INR 1.1 ± 0.12 1.1 ± 0.13 0.134 
TT (seconds) 20.0 ± 1.7 22.7 ± 1.9 0.000 
Fibrinogen (mg/dl) 483.2 ± 42.8 547.4 ± 46.2 0.000 
 
 
 
Fig (3): frequency of chronic diseases among gender 
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Table (9):  Multiple Comparisons TT and Fibrinogen level according to risk factor of other diseases 
Parameters Sample (I) Sample (II) Mean of (I) Mean of (II) P value 
TT (sec) No DM 22.9 ± 1.9 20.3 ± 2.3 0.007* 
No DM & HTN 22.9 ±1.9 20.2 ± 1.6 0.003* 
No HTN 22.9 ± 1.9 20.9 ± 2.2 0.020* 
No Other cardiac disease 22.9 ± 1.9 20.9 ± 1.9 0.066 
DM DM & HTN 20.3 ± 2.3 20.2 ± 1.6 0.838 
DM HTN 20.3 ± 2.3 20.9 ± 2.2 0.515 
DM Other cardiac disease 20.3 ± 2.3 20.9 ± 1.9 0.548 
HTN DM & HTN 20.9 ± 2.2 20.2 ± 1.6 0.374 
HTN Other cardiac disease 20.9 ± 2.2 20.9 ± 1.9 0.933 
Fibrinogen 
(mg/dl) 
No DM 555.3 ± 49.2 488.7 ± 55.4 0.005* 
No DM & HTN 555.3 ± 49.2 484.4 ± 38.3 0.002* 
No HTN 555.3 ± 49.2 501.0 ± 53.4 0.013* 
No Other cardiac disease 555.3 ± 49.2 504.3 ± 44.2 0.055 
DM DM & HTN 488.7 ± 55.4 484.4 ± 38.3 0.841 
DM HTN 488.7 ± 55.4 501.0 ± 53.4 0.548 
DM Other cardiac disease 488.7 ± 55.4 504.3 ± 44.2 0.541 
HTN DM & HTN 501.0 ± 53.4 484.4 ± 38.3 0.405 
HTN Other cardiac disease 501.0 ± 53.4 504.3 ± 44.2 0.890 
* The mean difference is significant at the 0.05 level. 
Table (10):  Comparison of PT, INR, TT and Fibrinogen level according to Exercise 
Parameters Exercise  (Mean ± SD)  P. value 
No  (n=38) Yes  (n=12) 
PT (seconds) 16.4 ± 1.4 16.2 ± 1.1 0.623 
INR 1.1± 0.1 1.1± 0.1 0.658 
TT (seconds) 21.1 ± 2.2 20.4 ± 2.2 0.336 
Fibrinogen (mg/dl) 508.6 ± 52.5 493.8 ± 56.2 0.408 
 
Table (11):  Correlations between Weight and TT 
Correlations 
  Weight TT 
Weight Pearson Correlation 1 -.063 
Sig. (2-tailed)  .663 
N 50 50 
TT Pearson Correlation -.063 1 
Sig. (2-tailed) .663  
N 50 50 
 
 
Fig (4): Correlations between Weight and TT 
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Table (12):  Correlations between Weight and Fibrinogen level 
Correlations 
  Weight Fibrinogen 
Weight Pearson Correlation 1 -.053 
Sig. (2-tailed)  .716 
N 50 50 
Fibrinogen Pearson Correlation -.053 1 
Sig. (2-tailed) .716  
N 50 50 
 
 
Fig (5): Correlations between Weight and Fibrinogen level 
DISCUSSION 
In the present study the results revealed the following: The 
descriptive statistics for myocardial infarction patients; 
mean of age (years) 61.5 and (Std deviation 14.2), mean of 
weight (kg) 74.9 (std deviation 7.9), mean of PT (second) 
16.4 (std deviation 1.3), mean of INR 1.1 (std deviation 0.13), 
mean of TT (second) 20.9 (std deviation 2.2) and mean of 
fibrinogen (mg/dl) 505.(std deviation53.2). Also, the 
Descriptive Statistics for control; mean of age (years) 28.9 
(std deviation 3.9), TT (second) 10.7 (std deviation 0.7) and 
mean of fibrinogen (mg/dl) 260.3  (std deviation15.8). The 
frequency of gender among study population; for the 
patients the males more than females, while in the control 
the females more than males. 
There was significant difference of age (years) in myocardial 
infarction patients when compared with control group 
(mean 61.5±Sd) (p.value 0.000) and the most affected age 
group above 60, that is consistent with other study which 
reported; acute myocardial infarction is generally caused by 
thrombus arising secondary to the rupture of the 
atherosclerotic plaque in coronary artery and usually affects 
adults over 40. Only 4% of AMI patients are under 40. [9,10]  
Also, there was significant difference of TT (second) in 
myocardial infraction patients when compared with control 
group (mean 20.9±SD) (p.value 0.000), that is agree with 
other study also showed a significant difference of thrombin 
time in patients with acute phase of MI. [11] Regarding the 
fibrinogen level our results showed; there was a significant 
difference of fibrinogen (mg/dl) in myocardial infraction 
patients when compared with control group (p.value 0.000),  
that is  consistent with other  study also  reported  that; the  
serum fibrinogen levels are a risk factor  for premature 
AMI.[12,13]  In the present study there was insignificant 
difference of age (years) in gender of myocardial infarction 
patients male when compared with female (p.value0.866). 
One of previous study agreed with our finding and reported 
that; the decline among women to be less consistent than 
that observed in men. [14] Also, there was insignificant 
difference of weight (kg) in gender of myocardial infraction 
male (mean 74.3±SD) when compared with female (mean 
76.3±SD) (p.value 0.520). In compare with other study said 
that; overweight is often regarded as one of the most 
important modifiable cardiovascular risk factors, but its 
association with cardiovascular health over a lifespan 
remains incompletely understood. Not all studies have 
demonstrated adverse effects of overweight. [15] 
There was insignificant difference of PT (second) and INR in 
gender of myocardial infraction male when compared with 
female (p.value 0.617) (p.value 0.422). That is agreed with 
other study which reported that;  prothrombin time (PT) and 
activated partial thromboplastin time(a PTT) didn’t show 
any significance among patients with AMI and  disagreed 
with other study showed;  both PT and a PTT are 
significantly increased in AMI patients on anticoagulation 
therapy. [16,17] Also, there was insignificant difference of PT 
(second) and INR in myocardial infraction patients not used 
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treatment for the chronic disease when compared with other 
used treatment (p.value0.229) (p.value0.422). In addition to 
that; there was insignificant difference of PT (second) and 
INR in myocardial infraction patient who didn’t smoke when 
compared with smoking patients (p.value0.068). In the other 
hands our results revealed that; there was significant 
difference of fibrinogen levels (mg/dl) and TT (second) in 
myocardial infraction male when compared with female (p. 
value 0.00) & (p. value 0.002).  Also, there was insignificant 
difference of fibrinogen levels (mg/dl)  and TT (second) in 
myocardial infraction patients that didn’t use treatment  
when compared with used treatment (p.value0.159) & 
(p.value0.146)  Indeed , the frequency of use treatment for 
chronic diseases among gender of study population;  male 
didn’t use treatment more than  female.  There was 
significant difference of fibrinogen levels (mg/dl) and TT 
(second) in myocardial infraction patients who did not 
smoke when compared with smoking patients 
(p.value0.000). Many studies confirmed that; Smoking is the 
most important and commonest risk factor in young patients. 
[18,19] 
In the present study the frequency of chronic diseases 
(hypertension, diabetes mellites and cardiac disease) among 
gender; male are more than the female in the study 
population, also there was significant difference for TT when 
compared patients of myocardial infraction with no risk 
factor (chronic diseases) with the patient with chronic 
diseases (DM P.V 0.007, HT P.V 0.003), while there was 
insignificant results when compered the two groups in the 
patients with the cardiac diseases  
For the fibrinogen levels there was a significant difference 
when compered between the patients with chronic disease 
with the patients without chronic diseases ( p value 0.002 for 
DM and p value 0.013 for HT) and in significant difference in 
the patient with cardic disease (p.value0.066). Many studies 
agreed with our results and revealed the same risk factors 
for AMI including age, smoking, cholesterol, physical 
inactivity, arterial hypertension, diabetes. [18,20,21] 
Finally there was insignificant difference of PT (second), INR, 
TT (second) and fibrinogen levels (mg/dl) when compered 
between the patients that were made exercise and the other 
were not.  also, there was significant difference when 
correlation between weight and TT and fibrinogen levels  
that is in agreed  with  other study  revealed   that ; both 
overweight and obesity increased the incidence of AMI [22], 
another study   showed that;  an independent relationship 
between them. [23] 
CONCLUSIONS 
Fibrinogen level was significantly increased in myocardial 
infarction patients, also here were significant differences 
related to age group, smoking and weight , however  PT, INR 
insignificantly increased  in myocardial infarction patient 
and there were insignificant differences related to exercise. 
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